U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.26 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.14 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3583
    -0.0108 (-0.79%)
     
  • USD/JPY

    103.8710
    +0.0550 (+0.05%)
     
  • BTC-USD

    36,889.72
    +36,889.72 (+0.00%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

LAWSUITS FILED AGAINST BIIB, SPLK and QSR - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

·3 min read

NEW YORK, NY / ACCESSWIRE / January 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Biogen Inc. (NASDAQ:BIIB)

CONTACT JAKUBOWITZ ABOUT BIIB:
https://claimyourloss.com/securities/biogen-inc-loss-submission-form/?id=12052&from=1

Class Period : October 22, 2019 - November 6, 2019

Lead Plaintiff Deadline : January 12, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Splunk Inc. (NASDAQ:SPLK)

CONTACT JAKUBOWITZ ABOUT SPLK:
https://claimyourloss.com/securities/splunk-inc-loss-submission-form/?id=12052&from=1

Class Period : October 21, 2020 - December 2, 2020

Lead Plaintiff Deadline : February 2, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Restaurant Brands International Inc. (NYSE:QSR)

CONTACT JAKUBOWITZ ABOUT QSR:
https://claimyourloss.com/securities/restaurant-brands-international-inc-loss-submission-form/?id=12052&from=1

Class Period : April 29, 2019 - October 28, 2019

Lead Plaintiff Deadline : February 19, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Winning Together Plan was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (2) the Tims Rewards loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/623726/LAWSUITS-FILED-AGAINST-BIIB-SPLK-and-QSR--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS